Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Timeline: Expected Clinical Trial Readouts For PD-1 Competitors

Scrip highlights the top data readouts expected over the next 12 months from the big PD-1/PD-L1 players, such as Bristol Myers Squibb and Merck & Co. – as well as a few compounds to watch out for earlier in the cancer immunotherapy pipeline.

Clinical Trials ImmunoOncology Research & Development

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class

One case of adjudicated arthropathy seen in halted Phase IIb study of anti-NGF candidate. Regeneron still hopes to advance fasinumab, partnered with Teva, into Phase III in osteoarthritis and chronic low back pain – but the second clinical hold for the class puts its future into even greater question.

Drug Safety Clinical Trials Deals

Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials

Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.

Research & Development Commercial Companies

TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.

Clinical Trials Neurology Research & Development

Pipeline Watch: Phase III Progress With Biosimilar Adalimumab And Trastuzumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials Approvals

Pipeline Watch - Four Approvals, Three Filings And One Partial Hold Lifted

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Clinical Trials Approvals Pipeline Watch

PIPELINE WATCH – 13 Approvals, 13 Opinions And Six Filings

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Clinical Trials Approvals Pipeline Watch

PIPELINE WATCH – 10 Approvals, Two Breakthroughs And A Refusal To File Letter

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Clinical Trials Approvals Pipeline Watch

Steps On The Long Road To Therapies For Uncontrolled Asthma

Orthopedics Respiratory

PCSK9 Inhibitors: What Does The Future Hold For This Controversial New Class?

The Future Looks Bright For Orphan Drugs

Designed to encourage clinical development in medical diseases that affect fewer than 200,000 people in the US, an orphan drug designation provides assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity.

Cancer
Advertisement
UsernamePublicRestriction

Register

Advertisement